Eisai and Seikagaku said on April 1 that they have inked a joint development and commercialization agreement in China for SI-613 (diclofenac conjugated sodium hyaluronate), an osteoarthritis treatment originated by the latter company. Under the deal, the two companies will…
To read the full story
Related Article
- Eisai, Seikagaku Tie Up on Osteoarthritis Med in South Korea
October 1, 2020
BUSINESS
- Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
March 13, 2026
- Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Half of Drug Makers Reluctantly Support G1 Rule Overhaul: Jiho Survey
March 12, 2026
- FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





